Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20302014 | 0.78 | — | — | |
| SCHEMBL1747774 | 0.70 | — | — | |
| SCHEMBL9608969 | 0.62 | SLC6A2 (0.45) | SLC6A2SLC6A3 | |
| SCHEMBL17824655 | 0.61 | SLC6A2 (0.44) | SLC6A2SLC6A3 | |
| SCHEMBL18648682 | 0.55 | — | — | |
| Isobutane SCHEMBL8394751 | 0.52 | — | — | |
| SCHEMBL10063452 | 0.51 | — | — | |
| SCHEMBL12922239 | 0.50 | ALDH1A1 (0.31) | — | |
| SCHEMBL18999978 | 0.47 | — | — | |
| Isopropyl Alcohol SCHEMBL563810 | 0.46 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817036-B1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2012-07-04 | — | — | EP | claimed |
| EP-1817036-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | claimed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | claimed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | claimed |
| EP-1817036-B1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2012-07-04 | — | — | EP | disclosed |
| US-7863449-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1817036-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | disclosed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270653-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | SLC6A2 787/4885SLC6A3 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.